We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AbbVie noted that the fourth-quarter loss was due to a $4.1-billion impairment charge related to intangible assets acquired as part of the acquisition of Stemcentrx in 2016 for $5.8 billion.